Physician profile
Christopher K Fuller
NPI 1962466961
$24,742.95
in general payments reported to CMS, 2019-2025
38 companies · $4,020 in 2025
The $4,020 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,912 · 2020: $2,691 · 2021: $1,450 · 2022: $1,533 · 2023: $1,752 · 2024: $7,386 · 2025: $4,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,255 · Consulting Fee: $4,150 · Travel and Lodging: $1,650 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,255.14 |
| Consulting Fee | $4,150.00 |
| Travel and Lodging | $1,650.29 |
| Education | $101.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $4,975.32 | 2023-2024 | Vtama |
| Epi Health, LLC | $2,801.34 | 2019-2020 | |
| Almirall LLC | $2,322.66 | 2019-2025 | Klisyri, Seysara |
| Abbvie INC. | $1,891.76 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $1,581.87 | 2025 | Tremfya |
| Genzyme Corporation | $1,499.24 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $969.35 | 2019-2025 | Absorica Ld, Winlevi, Blu-U |
| Arcutis Biotherapeutics, INC. | $811.54 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $809.15 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $742.36 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $663.96 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Pfizer INC. | $619.17 | 2019-2025 | |
| Amgen INC. | $596.98 | 2023-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $556.81 | 2019-2025 | |
| Galderma Laboratories, L.P. | $503.30 | 2019-2025 | Aklief, Nemluvio |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $355.16 | 2022-2025 | Opzelura |
| Ucb, INC. | $300.28 | 2019-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $299.78 | 2019-2025 | |
| Encore Dermatology INC. | $280.97 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $265.90 | 2019-2025 | Cabtreo, Siliq, Jublia |
| Allergan, INC. | $247.74 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $242.84 | 2023-2024 | Sotyktu |
| Genentech USA, INC. | $199.47 | 2019-2025 | Susvimo, Vabysmo |
| Vyne Pharmaceuticals INC. | $183.21 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.19 | 2023-2024 | Spevigo |
| Leo Pharma INC. | $159.84 | 2021-2025 | Adbry, Anzupgo |
| Dermira, INC. | $143.85 | 2019-2021 | |
| Biofrontera INC. | $127.51 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Sanofi-Aventis U.S. LLC | $99.99 | 2019 | |
| Organon LLC | $82.92 | 2025 | Vtama |
| Journey Medical Corporation | $55.91 | 2019-2025 | |
| Bausch & Lomb Americas INC. | $54.04 | 2023 | Miebo, Lotemax Sm |
| Medimetriks Pharmaceuticals, INC. | $33.34 | 2019-2020 | |
| Verrica Pharmaceuticals INC. | $24.95 | 2023 | Ycanth |
| Dusa Pharmaceuticals, INC. | $23.06 | 2019 | |
| Blueprint Medicines Corporation | $22.25 | 2025 | Ayvakit |
| Ocular Therapeutix, INC. | $21.00 | 2025 | Dextenza |
| Merck Sharp & Dohme LLC | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Fuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.